Summary
Schrodinger and Eli Lilly will make Lilly's TuneLab AI drug-discovery platform available through Schrodinger's LiveDesign cloud platform, expanding access to AI-driven workflows for biotech users. TuneLab is expected to roll out to existing LiveDesign customers in Q1 2026 and to new customers in Q2 2026, with a privacy-first federated learning approach so partner data stays local while models learn across multiple sources.
LiveDesign is already used by chemists to design compounds and predict properties, so the integration positions TuneLab as an add-on for teams already operating inside Schrodinger's software stack.
Signals for Investors
- Distribution matters: embedding TuneLab inside LiveDesign could accelerate adoption without building a separate enterprise channel.
- Federated learning suggests a scalable data network effect while preserving partner privacy, a potential moat if performance improves with more collaborators.
- Near-term value depends on conversion rates after the Q1/Q2 rollout and evidence that TuneLab improves hit rates or cycle times versus traditional workflows.
What to Watch Next
Track the Q1/Q2 2026 rollout milestones, pricing or usage terms, and whether the partnership surfaces measurable performance benchmarks or co-developed candidates advancing into preclinical or clinical stages.